Warning: The NCBI web site requires JavaScript to function. more...
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE.
Breast Cancer Res. 2006;8(4):R38.
Related citations
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa.
Staff S, Isola JJ, Johannsson O, Borg A, Tanner MM.
Br J Cancer. 2001 Oct 19;85(8):1201-5.
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE.
Breast Cancer Res. 2009;11(4):R47. Epub 2009 Jul 9. Erratum in: Breast Cancer Res. 2009;11(5):404.
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA.
Oncogene. 1998 Oct 1;17(13):1681-9.
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI.
Cancer Res. 2005 Dec 1;65(23):10692-9.
Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM.
Genes Chromosomes Cancer. 2000 Aug;28(4):432-42.
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG.
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9.
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome.
Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR.
Ann Oncol. 2000 Mar;11(3):307-13.
Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A; for the Institut Curie Breast Cancer Study Group.
Eur J Cancer. 2005 Oct;41(15):2304-11. Epub 2005 Sep 1.
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, Provencher D, Tonin PN.
BMC Cancer. 2008 Apr 10;8:96.
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.
Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A.
BMC Cancer. 2005 Oct 17;5:134.
p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E, Tancredi M, Aretini P, Cipollini G, Naccarato AG, Viacava P, Bevilacqua G, Caligo MA.
Breast Cancer Res Treat. 2003 Nov;82(1):1-9.
Low expression of bcl-2 in Brca1-associated breast cancers.
Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, Vincent-Salomon A, Fourquet A, Magdelenat H, Sastre-Garau X.
Br J Cancer. 2000 Nov;83(10):1318-22.
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.
Cancer Res. 2009 Apr 15;69(8):3625-33. Epub 2009 Mar 31.
BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
Snell C, Krypuy M, Wong EM; kConFab investigators, Loughrey MB, Dobrovic A.
Breast Cancer Res. 2008;10(1):R12. Epub 2008 Feb 12.
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
Johannsdottir HK, Jonsson G, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Heikkila P, Egilsson V, Olsson H, Johannsson OT, Nevanlinna H, Borg A, Barkardottir RB.
Int J Cancer. 2006 Sep 1;119(5):1052-60.
Methylation not a frequent "second hit" in tumors with germline BRCA mutations.
Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE.
Fam Cancer. 2009;8(4):339-46. Epub 2009 Apr 2.
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H.
Breast Cancer Res. 2005;7(4):R465-9. Epub 2005 Apr 21.
Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M, Zikan M, Dundr P, Matous B, Pohlreich P.
Hum Mutat. 2005 Mar;25(3):319.
Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.
Johannsdottir HK, Johannesdottir G, Agnarsson BA, Eerola H, Arason A, Johannsson OT, Heikkilä P, Egilsson V, Olsson H, Borg A, Nevanlinna H, Barkardottir RB.
Anticancer Res. 2004 Sep-Oct;24(5A):2681-7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on